NL300415I2 - - Google Patents

Download PDF

Info

Publication number
NL300415I2
NL300415I2 NL300415C NL300415C NL300415I2 NL 300415 I2 NL300415 I2 NL 300415I2 NL 300415 C NL300415 C NL 300415C NL 300415 C NL300415 C NL 300415C NL 300415 I2 NL300415 I2 NL 300415I2
Authority
NL
Netherlands
Application number
NL300415C
Other languages
Dutch (nl)
Other versions
NL300415I1 (nl
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of NL300415I1 publication Critical patent/NL300415I1/nl
Publication of NL300415I2 publication Critical patent/NL300415I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL300415C 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn NL300415I1 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine
PCT/EP2000/002468 WO2000056360A2 (en) 1999-03-19 2000-03-17 Vaccine against antigens from bacteriae

Publications (2)

Publication Number Publication Date
NL300415I1 NL300415I1 (nl) 2009-12-01
NL300415I2 true NL300415I2 (OSRAM) 2016-12-13

Family

ID=27451884

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300415C NL300415I1 (nl) 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn

Country Status (32)

Country Link
US (8) US20030147922A1 (OSRAM)
EP (6) EP2277535A3 (OSRAM)
JP (4) JP4846906B2 (OSRAM)
KR (3) KR20020000785A (OSRAM)
CN (3) CN1192798C (OSRAM)
AR (3) AR022963A1 (OSRAM)
AT (3) ATE459373T1 (OSRAM)
AU (3) AU750913B2 (OSRAM)
BE (1) BE1025464I2 (OSRAM)
BR (4) BR0009166A (OSRAM)
CA (3) CA2366314C (OSRAM)
CY (3) CY1107561T1 (OSRAM)
CZ (3) CZ303653B6 (OSRAM)
DE (4) DE60038166T2 (OSRAM)
DK (2) DK1162999T3 (OSRAM)
ES (3) ES2300255T3 (OSRAM)
FR (1) FR10C0008I2 (OSRAM)
HK (3) HK1043728B (OSRAM)
HU (4) HU229968B1 (OSRAM)
IL (5) IL145044A0 (OSRAM)
LU (1) LU91652I2 (OSRAM)
MX (1) MXPA01009452A (OSRAM)
MY (2) MY125202A (OSRAM)
NL (1) NL300415I1 (OSRAM)
NO (4) NO20014322L (OSRAM)
NZ (3) NZ513840A (OSRAM)
PL (3) PL355178A1 (OSRAM)
PT (2) PT1162999E (OSRAM)
SI (2) SI1163000T1 (OSRAM)
TR (3) TR200102736T2 (OSRAM)
TW (3) TWI235064B (OSRAM)
WO (3) WO2000056358A2 (OSRAM)

Families Citing this family (289)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
ATE355375T1 (de) 1996-01-04 2006-03-15 Novartis Vaccines & Diagnostic Bakterioferritin aus helicobacter pylori
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
DE60038166T2 (de) * 1999-03-19 2009-03-12 Glaxosmithkline Biologicals S.A., Rixensart Impfstoff gegen bakterielle antigene
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
ATE439372T1 (de) 2000-10-27 2009-08-15 Novartis Vaccines & Diagnostic NukleinsƤuren und proteine von gruppen a und b- streptokokken
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
GEP20053691B (en) 2001-01-23 2005-12-12 Pasteur Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine
JP5208347B2 (ja) 2001-02-23 2013-06-12 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ę–°č¦ćŖćƒÆć‚Æćƒćƒ³
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0109297D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
NZ562929A (en) 2001-12-12 2009-07-31 Novartis Vaccines & Diagnostic Immunisation against chlamydia trachomatis
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
ES2607431T3 (es) 2002-02-20 2017-03-31 Glaxosmithkline Biologicals Sa Micropartƭculas con molƩculas que contienen polipƩptidos adsorbidos
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthƤlt
JP4662537B2 (ja) * 2002-05-14 2011-03-30 ć‚«ć‚¤ćƒ­ćƒ³ ć‚½ćƒć‚Øć‚æ ć‚¢ ćƒ¬ć‚¹ćƒćƒ³ć‚µćƒ“ćƒŖć‚æ ćƒŖ惟ć‚æćƒ¼ć‚æ ē“°čŒę€§é«„č†œē‚Žć«é–¢ć™ć‚‹ē²˜č†œēµ„åˆć›ćƒÆć‚Æćƒćƒ³
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
ATE492288T1 (de) 2002-10-11 2011-01-15 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
EP1551869A2 (en) * 2002-10-15 2005-07-13 Intercell AG Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
KR101058978B1 (ko) 2002-11-01 2011-08-23 źø€ė½ģ†ŒģŠ¤ėÆøģŠ¤ķ“ė¼ģø ė°”ģ“ģ˜¤ė”œģ§€ģ¹¼ģ¦ˆ ģ—ģŠ¤.ģ—ģ“. ė©“ģ—­ģ›ģ„± ģ”°ģ„±ė¬¼
KR101062525B1 (ko) 2002-11-12 2011-09-06 ė” ėøŒė¦¬ź²€ ģ•¤ė“œ ģš°ėؼģ¦ˆ ķ•˜ģŠ¤ķ”¼ķ„ø, ģøķ¬. ķ¬ė„ģƒźµ¬ź·  ź°ģ—¼ģ— ėŒ€ķ•œ ė‹¤ė‹¹ė„˜ ė°±ģ‹ 
CA2506318C (en) 2002-11-15 2011-07-12 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP1578954A4 (en) 2002-12-11 2010-08-11 Coley Pharm Group Inc 5'-CPG NUCLEIC ACIDS AND USE METHOD
CA2511512C (en) 2002-12-27 2013-10-29 Chiron Corporation Immunogenic compositions containing phospholipid
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
CN102302776B (zh) 2003-01-30 2014-06-18 čÆŗ华ē–«č‹—å’ŒčÆŠę–­ęœ‰é™å…¬åø ęŠ—å¤šē§č„‘č†œē‚ŽēƒčŒč”€ęø…ē»„ēš„åÆę³Øå°„ę€§ē–«č‹—
US9296795B2 (en) 2003-03-07 2016-03-29 Wyeth Holdings, Llc. Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
KR101052996B1 (ko) * 2003-03-13 2011-07-29 źø€ė½ģ†ŒģŠ¤ėÆøģŠ¤ķ“ė¼ģø ė°”ģ“ģ˜¤ė”œģ§€ģ¹¼ģ¦ˆ ģ—ģŠ¤.ģ—ģ“. ė°•ķ…Œė¦¬ģ•„ ģ„øķ¬ģš©ķ•“ģ†Œģ— ėŒ€ķ•œ ģ •ģ œ ź³µģ •
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgĆ”nicos para la inmunopotenciaciĆ³n
DE602004022286D1 (de) 2003-06-02 2009-09-10 Novartis Vaccines & Diagnostic Immunogene zusammensetzungen auf basis von biologisch abbaubaren mikroteilchen enthaltend ein diphtherie- und ein tetanustoxoid
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CA2885040C (en) * 2003-10-02 2018-10-30 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
SI1740217T1 (sl) 2004-04-30 2011-10-28 Novartis Ag Konjugirano meningokokno cepljenje
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
SI2682126T1 (sl) 2005-01-27 2017-03-31 Children's Hospital & Research Center At Oakland Cepiva na osnovi veziklov, osnovanih na GNA1870, za Ŕirokospektralno zaŔčito proti boleznim, povzročenim z Neisserio meningitidisom
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
ATE552267T1 (de) 2005-02-18 2012-04-15 Novartis Vaccines & Diagnostic Immungene von uropathogenen escherichia coli
SG160329A1 (en) 2005-02-18 2010-04-29 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
CN113198013B (zh) 2005-04-08 2024-02-20 ęƒ ę°ęœ‰é™č“£ä»»å…¬åø 多价č‚ŗē‚ŽēƒčŒå¤šē³–ļ¼č›‹ē™½č“Øē¼€åˆē‰©ē»„合ē‰©
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
CN101500601A (zh) 2005-04-18 2009-08-05 čÆŗ华ē–«č‹—å’ŒčÆŠę–­å…¬åø č”Øč¾¾ē”ØäŗŽåˆ¶å¤‡ē–«č‹—ēš„ä¹™åž‹č‚ē‚Žē—…ęƒč”Øé¢ęŠ—åŽŸ
CA2611960C (en) 2005-06-27 2015-05-05 Glaxosmithkline Biologicals S.A. Immunogenic compositions comprising n.meningitidis capsular saccharide conjugates
EP1931380A2 (en) 2005-09-01 2008-06-18 Novartis Vaccines and Diagnostics GmbH & Co. KG Multiple vaccination including serogroup c meningococcus
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
AU2006335256B2 (en) 2005-11-22 2012-10-18 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa ꖰē©Žēµ„合ē‰©
PL3017827T3 (pl) * 2005-12-22 2019-04-30 Glaxosmithkline Biologicals Sa Szczepionka z koniugatem polisacharydu pneumokokowego
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
ES2809167T3 (es) * 2006-01-17 2021-03-03 Forsgren Arne Una novedosa proteĆ­na de Haemophilus influenzae expuesta en la superficie (proteĆ­na E; pE)
CN101024079B (zh) * 2006-02-17 2012-02-01 ē¦å·žę˜Œę™–ē”Ÿē‰©å·„ēØ‹ęœ‰é™å…¬åø č‚ŗē‚Žé“¾ēƒčŒå¤šē³–-å¤–č†œč›‹ē™½ē»“合ē–«č‹—åŠåˆ¶å¤‡ę–¹ę³•
CA2644724C (en) * 2006-03-17 2016-05-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for preparing complex multivalent immunogenic conjugates
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
TR201807355T4 (tr) 2006-03-22 2018-06-21 Glaxosmithkline Biologicals Sa Meningokokkal konjugatlarla immĆ¼nizasyon rejimleri.
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
PE20080129A1 (es) * 2006-03-30 2008-04-08 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
MX337528B (es) * 2006-03-30 2016-03-09 Glaxosmithkline Biolog Sa ComposiciĆ³n inmunogĆ©nica que comprende un sacĆ”rido capsular estafilocĆ³cico o-acetilado y una proteĆ­na estafilocĆ³cica.
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
WO2009030978A2 (en) * 2006-06-09 2009-03-12 Novartis Ag Conformers of bacterial adhesins
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
RU2460539C2 (ru) * 2006-10-10 2012-09-10 Š’Š°Š¹ŠµŃ‚ Š”ŠŸŠžŠ”ŠžŠ‘ ŠžŠ§Š˜Š”Š¢ŠšŠ˜ ŠŸŠžŠ›Š˜Š”ŠŠ„ŠŠ Š˜Š”ŠžŠ’ Streptococcus pneumoniae 3 Š¢Š˜ŠŸŠ (Š’ŠŠ Š˜ŠŠŠ¢Š«)
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EP2170379B1 (en) 2007-06-26 2017-03-22 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
BRPI0816689B1 (pt) 2007-09-12 2021-08-24 Novartis Ag ComposiĆ§Ć£o de vacina, kit e mĆ©todo para a confecĆ§Ć£o de uma composiĆ§Ć£o de vacina para a prevenĆ§Ć£o ou tratamento de infecĆ§Ć£o por streptococcus pyogenes
DK2200642T3 (da) 2007-10-19 2012-07-16 Novartis Ag MeningococvaccineprƦparater
JP2011503104A (ja) 2007-11-09 2011-01-27 ć‚«ćƒŖćƒ•ć‚©ćƒ«ćƒ‹ć‚¢ ć‚¤ćƒ³ć‚¹ćƒ†ć‚£ćƒ†ćƒ„ćƒ¼ćƒˆ ć‚Ŗ惖 惆ć‚Æ惎惭ć‚øćƒ¼ 免ē–«čŖæēƀ化合ē‰©ćŖć‚‰ć³ć«é–¢é€£ēµ„ęˆē‰©ćŠć‚ˆć³ę–¹ę³•
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
DK2235046T3 (da) 2007-12-21 2012-10-29 Novartis Ag Mutante former af streptolysin-O
EP2252326A4 (en) * 2008-02-01 2012-08-29 Newcastle Innovation Ltd VACCINE COMPOSITIONS
NZ596805A (en) 2008-02-21 2013-06-28 Novartis Ag Meningococcal fHBP polypeptides
AU2009223613B2 (en) 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
BRPI0916365A2 (pt) 2008-07-21 2018-05-02 Brigham & Womens Hospital Inc mƩtodos e composiƧƵes relacionados aos oligossacarƭdeos de glicosina beta-1,6 sintƩticos
PL2349520T3 (pl) 2008-10-27 2017-08-31 Glaxosmithkline Biologicals Sa SposĆ³b oczyszczania węglowodanĆ³w z paciorkowcĆ³w grupy a
PE20110891A1 (es) 2008-12-09 2011-12-23 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
US20100189737A1 (en) 2008-12-17 2010-07-29 Arico Beatrice Meningococcal vaccines including hemoglobin receptor
BRPI1005670A8 (pt) 2009-01-05 2017-12-26 Epitogenesis Inc composiƧƵes adjuvantes e processos de uso.
MX2011007456A (es) 2009-01-12 2011-08-03 Novartis Ag Antigenos del dominio de proteina de superficie de union a colageno tipo b (can_b) en vacunas contra bacteria gram positiva.
CN102427826B (zh) 2009-03-24 2014-11-26 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø äøŗ脑膜ē‚ŽēƒčŒå› å­hē»“åˆč›‹ē™½ę·»åŠ ä½å‰‚
WO2010109324A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
TWI469789B (zh) 2009-06-22 2015-01-21 Wyeth Llc é‡‘é»ƒč‰²č‘”č„ēƒčŒęŠ—原之免ē–«åŽŸę€§ēµ„合ē‰©
WO2011017101A2 (en) * 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
NZ598356A (en) 2009-07-30 2014-06-27 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
EP3017828A1 (en) 2009-08-27 2016-05-11 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
WO2011027257A2 (en) * 2009-09-03 2011-03-10 Pfizer Vaccines Llc Pcsk9 vaccine
KR20120081587A (ko) 2009-09-10 2012-07-19 ė…øķŒŒė„“ķ‹°ģŠ¤ ģ•„ź²Œ źø°ė„ ģ§ˆė³‘ģ— ėŒ€ķ•œ ģ”°ķ•© ė°±ģ‹ 
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
CN102971009A (zh) 2009-10-30 2013-03-13 čÆŗåŽęœ‰é™å…¬åø é‡‘é»„č‰²č‘”č„ēƒčŒ5型和8åž‹čšč†œå¤šē³–ēš„ēŗÆ化
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
CN102892753B (zh) 2009-12-17 2016-01-20 ę³•ēŗ³ē”Ÿē‰©č§£å†³åŠžę³•ęœ‰é™č“£ä»»å…¬åø åœØ制备ē¼€åˆē–«č‹—äø­ē”ØäŗŽę“»åŒ–多ē³–ēš„化学čƕ剂
KR20120120185A (ko) 2009-12-22 2012-11-01 ģ…€ė±ģŠ¤ ģŽ„ė¼ķ“Øķ‹±ģŠ¤, ģøķ¬. ė°±ģ‹  ģ”°ģ„±ė¬¼
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CN105315351A (zh) 2010-03-30 2016-02-10 å„„å…‹å…°å„æē«„医院及ē ”ē©¶äø­åæƒ ę”¹ę€§ēš„h因子ē»“åˆč›‹ē™½ļ¼ˆfhbpļ¼‰åŠå…¶ä½æē”Øę–¹ę³•
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP2555753B1 (en) 2010-04-07 2018-08-01 California Institute of Technology Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
JP2013530949A (ja) * 2010-05-20 2013-08-01 ć‚Ø惫 ćƒ©ć‚¦ćƒ³ćƒ‰ ć‚øćƒ„ćƒ¼ćƒ³ ęŠ—åŽŸē‰¹ē•°ēš„ļ¼“ļ½’ļ½…ļ½‡äø¦ć³ć«é–¢é€£ć™ć‚‹ēµ„ęˆē‰©ć€ę–¹ę³•åŠć³ć‚·ć‚¹ćƒ†ćƒ 
CN102933229A (zh) * 2010-06-04 2013-02-13 ęƒ ę°ęœ‰é™č“£ä»»å…¬åø ē–«č‹—制剂
EP2942061A3 (en) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
CA2798837A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
WO2012103421A1 (en) 2011-01-27 2012-08-02 Novartis Ag Adjuvant nanoemulsions with crystallisation inhibitors
EP2680885B8 (en) 2011-03-02 2018-07-25 GlaxoSmithKline Biologicals SA Combination vaccines with lower doses of antigen and/or adjuvant
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
EP2688590B1 (en) 2011-03-24 2020-02-12 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with phospholipids
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
EP2705853B1 (en) 2011-05-06 2018-07-18 Aparin, Petr Gennadievich Exopolysaccharide of shigella sonnei bacteria, method for producing same, vaccine and pharmaceutical composition containing same
AU2012272652B2 (en) 2011-06-24 2017-06-01 Epitogenesis Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
EP2729178A1 (en) 2011-07-08 2014-05-14 Novartis AG Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
CN103917245B (zh) 2011-09-14 2017-06-06 č‘›å…°ē“ å²åƆäøå…‹čŽ±ę©ē”Ÿē‰©ęœ‰é™å…¬åø ē”ØäŗŽåˆ¶å¤‡ē³–ā€‘蛋ē™½č“Øē³–ē¼€åˆē‰©ēš„ę–¹ę³•
US20140235667A1 (en) 2011-09-22 2014-08-21 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
CN104080479B (zh) 2011-11-07 2019-11-05 č‘›å…°ē“ å²åƆäøå…‹čŽ±ę©ē”Ÿē‰©ęœ‰é™å…¬åø åŒ…ę‹¬spr0096和spr2021ęŠ—åŽŸēš„čæč½½ä½“分子
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
AU2012349753A1 (en) 2011-12-08 2014-06-19 Novartis Ag Clostridium difficile toxin-based vaccine
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
AU2011384634A1 (en) 2011-12-29 2014-06-19 Novartis Ag Adjuvanted combinations of meningococcal factor H binding proteins
JP2015509713A (ja) 2012-02-24 2015-04-02 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ē·šęƛć‚æćƒ³ćƒ‘ć‚Æč³ŖćŠć‚ˆć³ēµ„ęˆē‰©
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
CN104159603A (zh) 2012-03-08 2014-11-19 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø åø¦ęœ‰tlr4ęæ€åŠØ剂ēš„č”åˆē–«č‹—
SA115360586B1 (ar) 2012-03-09 2017-04-12 ŁŲ§ŁŠŲ²Ų± Ų§Ł†Łƒ ŲŖŲ±ŁƒŁŠŲØŲ§ŲŖ Ł„Ų¹Ł„Ų§Ų¬ Ų§Ł„Ų§Ł„ŲŖŁ‡Ų§ŲØ Ų§Ł„Ų³Ų­Ų§Ų¦ŁŠ Ų§Ł„ŲØŁƒŲŖŁŠŲ±ŁŠ ŁˆŲ·Ų±Ł‚ Ł„ŲŖŲ­Ų¶ŁŠŲ±Ł‡Ų§
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
KR102139959B1 (ko) 2012-04-26 2020-08-04 ė…øķŒŒė„“ķ‹°ģŠ¤ ģ•„ź²Œ ķ•­ģ› ė° ķ•­ģ› ģ”°ķ•©ė¬¼
SG11201406592QA (en) 2012-05-04 2014-11-27 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
EP2852414B9 (en) 2012-05-22 2020-12-09 GlaxoSmithKline Biologicals SA Meningococcus serogroup x conjugate
KR102057217B1 (ko) 2012-06-20 2020-01-22 ģ—ģŠ¤ģ¼€ģ“ė°”ģ“ģ˜¤ģ‚¬ģ“ģ–øģŠ¤ ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
JP6324961B2 (ja) 2012-09-06 2018-05-16 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ 蔀ęø…ē¾¤ļ½‚é«„č†œē‚ŽčŒćØļ½„ļ¼ļ½”ļ¼ļ½ćØ恮ēµ„ćæåˆć‚ć›ćƒÆć‚Æćƒćƒ³
KR20150073943A (ko) 2012-10-03 2015-07-01 źø€ė½ģ†ŒģŠ¤ėÆøģŠ¤ķ“ė¼ģø ė°”ģ“ģ˜¤ė”œģ§€ģ¹¼ģ¦ˆ ģ—ģŠ¤.ģ—ģ“. ė©“ģ—­ģ›ģ„± ģ”°ģ„±ė¬¼
US20150273036A1 (en) 2012-10-12 2015-10-01 Glaxosmithkline Biologicals Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
BR112015008418A2 (pt) * 2012-10-17 2017-07-04 Glaxosmithkline Biologicals Sa uso de uma composiĆ§Ć£o imunogĆŖnica, composiĆ§Ć£o imunogĆŖnica, e, mĆ©todos para intensificar atividade opsĆ“nica mediada por anticorpo contra um sorotipo alvejado de streptococcus pneumoniae em um indivĆ­duo e para imunizar um hospedeiro humano contra doenƧas causadas por infecĆ§Ć£o por streptococcus pneumoniae
KR20140075201A (ko) * 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
KR20140075196A (ko) 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
WO2014118305A1 (en) 2013-02-01 2014-08-07 Novartis Ag Intradermal delivery of immunological compositions comprising toll-like receptor agonists
WO2014182966A1 (en) 2013-05-10 2014-11-13 California Institute Of Technology Probiotic prevention and treatment of colon cancer
JP2016520077A (ja) 2013-05-15 2016-07-11 悶 ć‚¬ćƒćƒŠćƒ¼ć‚ŗ ć‚Ŗ惖 悶 ćƒ¦ćƒ‹ćƒćƒ¼ć‚·ćƒ†ć‚£ ć‚Ŗ惖 ć‚¢ćƒ«ćƒćƒ¼ć‚æ ļ¼„ļ¼‘ļ½…ļ¼’ļ½ˆļ½ƒļ½–ćƒÆć‚Æćƒćƒ³åŠć³ä½æē”Øę–¹ę³•
CN103386126B (zh) * 2013-06-25 2015-06-17 北äŗ¬ē§‘å…“ē”Ÿē‰©åˆ¶å“ęœ‰é™å…¬åø äø€ē§å«č‚ é“ē—…ęÆ’ęŠ—åŽŸēš„多价免ē–«åŽŸę€§ē»„合ē‰©
KR20180099912A (ko) 2013-09-08 2018-09-05 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ė‚˜ģ“ģ„øė¦¬ģ•„ ė©”ė‹Œģ§€ķ‹°ė””ģŠ¤ ģ”°ģ„±ė¬¼ ė° ź·øģ˜ ė°©ė²•
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
CN106102770B (zh) 2014-01-21 2022-03-22 č¾‰ē‘žå…¬åø 包含ē¼€åˆčšč†œē³–ęŠ—åŽŸēš„免ē–«åŽŸę€§ē»„合ē‰©åŠå…¶ē”Ø途
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PT3096783T (pt) 2014-01-21 2021-08-16 Pfizer PolissacƔridos capsulares de streptococcus pneumoniae e conjugados dos mesmos
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
PL3110442T3 (pl) 2014-02-28 2021-04-19 Glaxosmithkline Biologicals Sa Zmodyfikowane meningokokowe polipeptydy fhbp
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
CN104829711B (zh) * 2014-04-08 2018-04-03 北äŗ¬å¤©ęˆę–°č„‰ē”Ÿē‰©ęŠ€ęœÆęœ‰é™å…¬åø 脑膜ē‚ŽēƒčŒčšč†œå¤šē³–å•å…‹éš†ęŠ—ä½“åŠå…¶åŗ”ē”Ø
RU2714248C2 (ru) 2014-07-23 2020-02-13 Š§ŠøŠ»Š“рŠµŠ½'Š— Š„Š¾ŃŠæŠøтŠ°Š» Š­Š½Š“ Š Šøсёрч Š”ŠµŠ½Ń‚ŠµŃ€ Š­Ń‚ ŠžŠŗŠ»ŠµŠ½Š“ Š’Š°Ń€ŠøŠ°Š½Ń‚Ń‹ фŠ°ŠŗтŠ¾Ń€ Š½-сŠ²ŃŠ·Ń‹Š²Š°ŃŽŃ‰ŠµŠ³Š¾ Š±ŠµŠ»ŠŗŠ° Šø сŠæŠ¾ŃŠ¾Š±Ń‹ Šøх ŠæрŠøŠ¼ŠµŠ½ŠµŠ½Šøя
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
IL252915B2 (en) 2015-01-15 2024-04-01 Pfizer Immunogenic compositions for use in pneumococcal vaccines
CN104548090B (zh) * 2015-01-27 2016-11-30 äø­å›½ē§‘学院čæ‡ēØ‹å·„ē؋ē ”ē©¶ę‰€ äø€ē§Ī²-葔聚ē³–äæ®é„°ēš„č„‘č†œē‚Žå¤šē³–ē»“合ē–«č‹—åŠå…¶åˆ¶å¤‡ę–¹ę³•
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
CA2991544A1 (en) 2015-07-07 2017-01-12 Affiris Ag Vaccines for the treatment and prevention of ige mediated diseases
IL303998A (en) 2015-07-21 2023-08-01 Pfizer Immunogenic preparations containing conjugated capsular sugar antigens, kits containing them and their uses
EP4480544A3 (en) 2015-08-25 2025-03-26 Babita Agrawal Immunomodulatory compositions andmethods of use thereof
EP4491735A3 (en) 2015-10-08 2025-04-16 The Governors of the University of Alberta Hepatitis c virus e1/e2 heterodimers and methods of producing same
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CU20210061A7 (es) 2015-12-04 2022-02-04 Dana Farber Cancer Inst Inc ComposiciĆ³n vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cĆ”ncer
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
TWI709647B (zh) 2016-01-19 2020-11-11 ē¾Žå•†č¼ē‘žč‚”ä»½ęœ‰é™å…¬åø ē™Œē—‡ē–«č‹—
EP3439704A1 (en) 2016-04-05 2019-02-13 GSK Vaccines S.r.l. Immunogenic compositions
WO2017220753A1 (en) 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Fƶrderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
BR112019001995A2 (pt) 2016-08-05 2019-05-07 Sanofi Pasteur, Inc. composiĆ§Ć£o de conjugado de polissacarĆ­deo pneumocĆ³cico multivalente ? proteĆ­na
US11241489B2 (en) 2016-08-05 2022-02-08 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2018042017A2 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
CN110022893B (zh) 2016-10-07 2023-12-29 ꁩē‰¹ē½—姆公åø ē”ØäŗŽē™Œē—‡ē–—ę³•ēš„免ē–«åŽŸę€§åŒ–合ē‰©
CN110022894B (zh) 2016-10-07 2024-01-19 ꁩē‰¹ē½—姆公åø ē”ØäŗŽē™Œē—‡ē–—ę³•ēš„免ē–«åŽŸę€§åŒ–合ē‰©
BE1025162B9 (fr) 2016-12-06 2019-01-07 Glaxosmithkline Biologicals Sa Procede de purification pour les polysaccharides capsulaires
BR112019014833A2 (pt) 2017-01-20 2020-04-14 Pfizer composiƧƵes imunogĆŖnicas para uso em vacinas pneumococais
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2018169303A1 (ko) * 2017-03-15 2018-09-20 ģ£¼ģ‹ķšŒģ‚¬ ģ—˜ģ§€ķ™”ķ•™ ė‹¤ź°€ ķė “źµ¬ź·  ė°±ģ‹  ģ”°ģ„±ė¬¼
EP3600391A1 (en) 2017-03-31 2020-02-05 GlaxoSmithKline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CN118356485A (zh) 2017-06-10 2024-07-19 åˆ›čµå…¬åø ęä¾›ę”¹å–„ēš„免ē–«åŽŸę€§å’Œäŗ²åˆåŠ›ēš„å…·ęœ‰äŗŒä»·ęˆ–多价ē¼€åˆē‰©å¤šē³–ēš„多价ē¼€åˆē‰©ē–«č‹—
BR112020001768A2 (pt) 2017-08-14 2020-09-29 Glaxosmithkline Biologicals S.A. mĆ©todo de reforƧar uma resposta imune prĆ©-existente contra haemophilus influenzae e moraxella catarrhalis nĆ£o tipĆ”veis em um indivĆ­duo, e, protocolo de vacinaĆ§Ć£o.
EP3691677A4 (en) 2017-10-04 2021-07-07 Pogona, Llc COMPOSITIONS OF SACCHARIDE-POLYPEPTIDE CONJUGATES AND THEIR METHODS OF USE
BR112020011414B8 (pt) 2017-12-06 2023-01-31 Merck Sharp & Dohme ComposiƧƵes imunogĆŖnicas multivalentes compreendendo conjugados de proteĆ­na carreadora e polissacarĆ­deo de s. pneumoniae
AU2019215212B2 (en) 2018-02-05 2025-05-15 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
US11123417B2 (en) 2018-02-05 2021-09-21 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
WO2019197563A2 (en) 2018-04-11 2019-10-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
EP3773689B1 (en) 2018-04-11 2022-11-09 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
KR20190121713A (ko) 2018-04-18 2019-10-28 ģ—ģŠ¤ģ¼€ģ“ė°”ģ“ģ˜¤ģ‚¬ģ“ģ–øģŠ¤(ģ£¼) ģŠ¤ķŠøė ™ķ† ģ½”ģ»¤ģŠ¤ ė‰“ėŖØė‹ˆģ•  ķ˜‘ė§‰ ė‹¤ė‹¹ė„˜ ė° ź·øģ˜ ė©“ģ—­ģ›ģ„± ģ ‘ķ•©ģ²“
EP3824019A1 (en) 2018-07-19 2021-05-26 GlaxoSmithKline Biologicals SA Processes for preparing dried polysaccharides
JP2021533162A (ja) 2018-08-07 2021-12-02 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ćƒ—ćƒ­ć‚»ć‚¹åŠć³ćƒÆć‚Æćƒćƒ³
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3894431A2 (en) 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Modified carrier proteins for o-linked glycosylation
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
KR20240169145A (ko) 2018-12-19 2024-12-02 ėØøķ¬ ģƒ¤ķ”„ ģ•¤ė“œ ė” ģ—˜ģ—˜ģ”Ø ģŠ¤ķŠøė ™ķ† ģ½”ģæ ģŠ¤ ė‰“ėŖØė‹ˆģ•„ģ— ķ“ė¦¬ģ‚¬ģ¹“ė¼ģ“ė“œ-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ė„¼ ķ¬ķ•Øķ•˜ėŠ” ģ”°ģ„±ė¬¼ ė° ź·øģ˜ ģ‚¬ģš© ė°©ė²•
CA3126492A1 (en) 2019-01-11 2020-07-16 Northwestern University Bioconjugate vaccines synthesis in prokaryotic cell lysates
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
WO2020165711A1 (en) 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidiscompositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ē“°čŒå¤šē³–锞悒ē²¾č£½ć™ć‚‹ćŸć‚ć®ę–¹ę³•
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
CA3139257A1 (en) 2019-05-10 2020-11-19 Glaxosmithkline Biologicals Sa Conjugate production
JP2022543281A (ja) 2019-08-05 2022-10-11 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  免ē–«åŽŸę€§ēµ„ęˆē‰©
US20230248816A9 (en) 2019-08-05 2023-08-10 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein d polypeptide
US12383611B2 (en) 2019-09-27 2025-08-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP4045150B1 (en) 2019-10-16 2025-11-26 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
MX2022005252A (es) 2019-11-01 2022-06-08 Pfizer Composiciones de escherichia coli y metodos de las mismas.
MX2022005704A (es) 2019-11-15 2022-06-08 Enterome S A Peptidos antigenicos para la prevencion y el tratamiento de malignidad de celulas b.
MX2022006054A (es) 2019-11-22 2022-06-24 Glaxosmithkline Biologicals Sa Dosificacion y administracion de una vacuna de glucoconjugados de sacaridos bacterianos.
WO2021138495A1 (en) * 2019-12-30 2021-07-08 Fraunhofer Usa, Inc. Particles for multi-dose delivery
US20230085173A1 (en) 2020-02-21 2023-03-16 Pfizer Inc. Purification of saccharides
WO2021165928A2 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
CN111588847B (zh) * 2020-05-18 2023-05-26 å¹æ州äø­åŒ»čÆ大学(å¹æ州äø­åŒ»čÆē ”ē©¶é™¢) äø€ē§å«ęœ‰å•ē£·é…ø化ēš„č„‚č“ØaäøŽē³–ęŠ—åŽŸēš„ē¼€åˆē‰©åŠå…¶åˆ¶å¤‡ę–¹ę³•å’Œåŗ”ē”Ø
US20230250142A1 (en) 2020-06-12 2023-08-10 Glaxosmithkline Biologicals Sa Dock tag system
US12053515B2 (en) 2020-08-10 2024-08-06 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
TW202227467A (zh) 2020-10-27 2022-07-16 ē¾Žå•†č¼ē‘žå¤§č—„å»  大č…øę”æ菌ēµ„合ē‰©åŠå…¶ę–¹ę³•
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
IL302413A (en) 2020-11-04 2023-06-01 Pfizer Immunogenic preparations for use in pneumococcal vaccines
JP2023549736A (ja) 2020-11-10 2023-11-29 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆć•ć›ćŸčŽ¢č†œē³–ęŠ—åŽŸć‚’å«ć‚€å…ē–«åŽŸę€§ēµ„ęˆē‰©ćŠć‚ˆć³ćć®ä½æē”Ø
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
AU2022223712A1 (en) 2021-02-19 2023-10-05 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
EP4294433A1 (en) 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Immunogenic composition, use and methods
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
TW202306969A (zh) 2021-05-28 2023-02-16 ē¾Žå•†č¼ē‘žå¤§č—„å»  包含ēµåˆä¹‹čŽ¢č†œé†£ęŠ—原ēš„免ē–«åŽŸēµ„合ē‰©åŠå…¶ē”Ø途
AU2022281543A1 (en) 2021-05-28 2023-11-23 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3237496A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
AU2023207315A1 (en) 2022-01-13 2024-06-27 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20250163484A1 (en) 2022-02-25 2025-05-22 Pfizer Inc. Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides
JP2025511086A (ja) 2022-03-31 2025-04-15 ć‚¢ćƒ³ćƒ†ćƒ­ćƒ¼ćƒ ćƒ»ć‚Øć‚¹ćƒ»ć‚¢ ē™Œć®é˜²ę­¢åŠć³å‡¦ē½®ć®ćŸć‚ć®ęŠ—åŽŸę€§ćƒšćƒ—ćƒćƒ‰
EP4522208A1 (en) 2022-05-11 2025-03-19 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
EP4622665A2 (en) 2022-11-22 2025-10-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024246082A1 (en) 2023-03-30 2025-10-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025109417A1 (en) 2023-11-21 2025-05-30 Panacea Biotec Limited Immunogenic composition of haemophilus influenzae conjugated to protein d
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
CN120404993B (zh) * 2025-07-03 2025-10-03 ęˆéƒ½čæˆē§‘åŗ·ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø äø€ē§ę£€ęµ‹ę ·ęœ¬äø­mplēš„ę–¹ę³•åŠå…¶ē›ø关åŗ”ē”Ø

Family Cites Families (58)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990006951A1 (en) * 1988-12-16 1990-06-28 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
JP3755890B2 (ja) 1992-06-25 2006-03-15 ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ćƒ»ćƒ“ćƒ¼ćƒćƒ£ćƒ ćƒ»ćƒć‚¤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚¹ļ¼ˆć‚½ć‚·ć‚Øćƒ†ćƒ»ć‚¢ćƒŽćƒ‹ćƒ ļ¼‰ ć‚¢ć‚øćƒ„ćƒćƒ³ćƒˆå«ęœ‰ćƒÆć‚Æćƒćƒ³ēµ„ęˆē‰©
CA2123580C (en) * 1992-09-16 2005-04-26 James B. Dale Antigen of hybrid m protein and carrier for group a streptococcal vaccine
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
DK0699076T3 (da) 1993-05-18 2003-03-03 Univ Ohio State Res Found Vaccine mod mellemĆørebetƦndelse
KR100376361B1 (ko) 1993-09-22 2003-07-18 ķ—Øė¦¬ ģ— . ģž­ģŠØ ķŒŒģš“ė°ģ“ģ…˜ ķ¬ ė” ģ–“ė“œė²¤ģŠ¤ėؼķŠø ģ˜¤ėøŒ ė°€ė¦¬ķ„°ė¦¬ ė©”ė””ģ‹  ė©“ģ—­ģ›ģ„±źµ¬ģ”°ģ²“ģ˜ģ œģ”°ė„¼ģœ„ķ•˜ģ—¬ģ‹ ź·œķ•œģ‹œģ•„ė‹ė ˆģ“ķŒ…ģ‹œģ•½ģ„ģ‚¬ģš©ķ•˜ģ—¬ģš©ķ•“ģ„±ķƒ„ģˆ˜ķ™”ė¬¼ģ„ķ™œģ„±ķ™”ķ•˜ėŠ”ė°©ė²•
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
DE69535036T3 (de) 1994-07-15 2011-07-07 The University of Iowa Research Foundation, IA Immunomodulatorische oligonukleotide
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
WO1996032963A1 (en) * 1995-04-17 1996-10-24 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
UA56132C2 (uk) * 1995-04-25 2003-05-15 Š”Š¼Ń–Ń‚ŠŗŠ»Š°Š¹Š½ Š‘ічŠµŠ¼ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶Ń–ŠŗŠ°Š»Ń Š”.Š. ŠšŠ¾Š¼ŠæŠ¾Š·Šøція Š²Š°ŠŗцŠøŠ½Šø (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± стŠ°Š±Ń–Š»Ń–Š·Š°Ń†Ń–Ń— qs21 Š²Ń–Š“Š½Š¾ŃŠ½Š¾ Š³Ń–Š“рŠ¾Š»Ń–Š·Ńƒ (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± ŠæрŠøŠ³Š¾Ń‚ŃƒŠ²Š°Š½Š½Ń ŠŗŠ¾Š¼ŠæŠ¾Š·Šøції Š²Š°ŠŗцŠøŠ½Šø
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
WO1996040928A1 (en) 1995-06-07 1996-12-19 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the hsp70 family
JP4233113B2 (ja) 1995-06-07 2009-03-04 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ćƒ»ćƒć‚¤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚¹ćƒ»ć‚½ć‚·ć‚Øćƒ†ćƒ»ć‚¢ćƒŽćƒ‹ćƒ  多ē³–é”žęŠ—åŽŸāˆ’ć‚­ćƒ£ćƒŖć‚¢č›‹ē™½ęŽ„åˆä½“ćŠć‚ˆć³éŠé›¢ć‚­ćƒ£ćƒŖć‚¢č›‹ē™½ć‚’ęœ‰ć—ć¦ćŖ悋ćƒÆć‚Æćƒćƒ³
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
CA2253252A1 (en) 1996-05-01 1997-11-06 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk ć‚°ćƒ¬ćƒ¼ćƒćƒ³ć‚°
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
WO1998055606A2 (en) 1997-06-03 1998-12-10 Connaught Laboratories Limited Lactoferrin receptor genes of moraxella
KR100619350B1 (ko) 1997-07-21 2006-09-05 ė°•ģŠ¤ķ„° ķ—¬ģ“°ģ¼€ģ–“ ģ—ģŠ¤.ģ—ģ“. ė³€ķ˜• ė©“ģ—­ģ„± ė‰“ė©€ė¦¬ģ‹  ė°±ģ‹ ģ”°ģ„±ė¬¼
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
CN1200731C (zh) 1998-04-07 2005-05-11 免ē–«åŒ»ē–—å…¬åø ē”Ø作ē–«č‹—ēš„č‚ŗē‚ŽēƒčŒčƒ†ē¢±ē»“åˆč›‹ē™½č”ē”Ÿē‰©
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
KR100704826B1 (ko) 1998-08-19 2007-04-09 ė°•ģŠ¤ķ„° ķ—¬ģ“°ģ¼€ģ–“ ģ—ģŠ¤.ģ—ģ“. ļ¼®-ģ•„ķ¬ė¦“ė”œģ¼ķ™”ėœ ķ“ė¦¬ģ‚¬ģ¹“ė¼ģ“ė“œė„¼ ģ‚¬ģš©ķ•˜ģ—¬ ģ œģ”°ėœė°±ģ‹ ģœ¼ė”œģ„œ ģ‚¬ģš©ķ•˜źø°ģ— ģ ķ•©ķ•œ ė©“ģ—­ģ›ģ„±Ī²-ķ”„ė”œķ”¼ģ˜Øģ•„ėÆøė„-ź²°ķ•© ķ“ė¦¬ģ‚¬ģ¹“ė¼ģ“ė“œ ė‹Øė°±ģ§ˆ ģ»Øģ„¬ź²Œģ“ķŠø
US6582706B1 (en) * 1998-12-21 2003-06-24 Medimmune, Inc. Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS
DE60038166T2 (de) 1999-03-19 2009-03-12 Glaxosmithkline Biologicals S.A., Rixensart Impfstoff gegen bakterielle antigene
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 åƌ士åŗ·(ę˜†å±±)ē”µč„‘ęŽ„ę’ä»¶ęœ‰é™å…¬åø ēŗæē¼†čæžęŽ„å™Øē»„件

Also Published As

Publication number Publication date
NO330532B1 (no) 2011-05-09
TWI281403B (en) 2007-05-21
SI1163000T1 (sl) 2008-06-30
IL145043A0 (en) 2002-06-30
TWI286938B (en) 2007-09-21
CY1107561T1 (el) 2013-03-13
US20060093626A1 (en) 2006-05-04
HUP0200664A2 (en) 2002-06-29
KR100798212B1 (ko) 2008-01-24
CN1391481A (zh) 2003-01-15
PT1163000E (pt) 2008-03-20
US20100291138A1 (en) 2010-11-18
HUS1500040I1 (hu) 2018-05-28
PL204890B1 (pl) 2010-02-26
AU750762B2 (en) 2002-07-25
CZ303653B6 (cs) 2013-01-30
AU750913B2 (en) 2002-08-01
HUP0200373A2 (en) 2002-06-29
US20030147922A1 (en) 2003-08-07
PL355178A1 (en) 2004-04-05
NO20014322L (no) 2001-11-14
HK1043728A1 (en) 2002-09-27
NO20014325L (no) 2001-11-14
CZ20013380A3 (cs) 2002-03-13
ES2275499T3 (es) 2007-06-16
US9168313B2 (en) 2015-10-27
EP1163000A2 (en) 2001-12-19
BR0009166A (pt) 2001-12-26
US20110217329A1 (en) 2011-09-08
AR022965A1 (es) 2002-09-04
US20060002961A1 (en) 2006-01-05
KR20020000549A (ko) 2002-01-05
CN1191852C (zh) 2005-03-09
HUP0200367A2 (en) 2002-05-29
NO20014323L (no) 2001-11-14
US20150079125A1 (en) 2015-03-19
US8926985B2 (en) 2015-01-06
CZ20013379A3 (cs) 2002-03-13
IL145043A (en) 2007-06-17
MXPA01009452A (es) 2002-08-06
NL300415I1 (nl) 2009-12-01
HK1043731B (en) 2009-01-23
JP4846906B2 (ja) 2011-12-28
CA2366152A1 (en) 2000-09-28
CN100339130C (zh) 2007-09-26
DE60038166T2 (de) 2009-03-12
TWI235064B (en) 2005-07-01
DK1162999T3 (da) 2007-03-26
IL145045A0 (en) 2002-06-30
CZ301445B6 (cs) 2010-03-03
NO330736B1 (no) 2011-06-27
PL203917B1 (pl) 2009-11-30
EP1162999A2 (en) 2001-12-19
CN1351501A (zh) 2002-05-29
ES2339737T3 (es) 2010-05-25
NO2011014I2 (no) 2011-08-30
DE122009000054I1 (de) 2009-12-31
WO2000056360A2 (en) 2000-09-28
PT1162999E (pt) 2007-02-28
TR200102736T2 (tr) 2002-04-22
EP1880735A2 (en) 2008-01-23
ATE459373T1 (de) 2010-03-15
DE60032120D1 (de) 2007-01-11
HK1043730A1 (zh) 2002-09-27
PL355180A1 (en) 2004-04-05
JP5551579B2 (ja) 2014-07-16
CY2009014I1 (el) 2010-07-28
MY125387A (en) 2006-07-31
CN1192798C (zh) 2005-03-16
KR20020001785A (ko) 2002-01-09
HU229968B1 (hu) 2015-03-30
WO2000056359A2 (en) 2000-09-28
NO2011014I1 (no) 2011-09-19
TR200102739T2 (tr) 2001-12-21
EP1880735A3 (en) 2008-03-12
WO2000056359A3 (en) 2001-02-01
DE60038166D1 (de) 2008-04-10
AU750788B2 (en) 2002-07-25
ATE346608T1 (de) 2006-12-15
CA2366314A1 (en) 2000-09-28
EP2277535A3 (en) 2011-03-09
AR022963A1 (es) 2002-09-04
HK1043731A1 (en) 2002-09-27
NO20014322D0 (no) 2001-09-05
WO2000056358A3 (en) 2001-01-04
IL145044A (en) 2007-03-08
CY1107390T1 (el) 2010-07-28
HK1043728B (en) 2007-06-22
CY2009014I2 (el) 2010-07-28
LU91652I9 (OSRAM) 2019-01-03
NO20014325D0 (no) 2001-09-05
HU228499B1 (en) 2013-03-28
BRPI0009163B8 (pt) 2021-05-25
LU91652I2 (fr) 2010-10-13
ES2300255T3 (es) 2008-06-16
EP1162999B1 (en) 2006-11-29
EP2277535A2 (en) 2011-01-26
CA2366314C (en) 2012-01-10
PL355264A1 (en) 2004-04-05
DK1163000T3 (da) 2008-04-28
AR022964A1 (es) 2002-09-04
EP1162998A2 (en) 2001-12-19
FR10C0008I1 (fr) 2010-03-26
CA2365296A1 (en) 2000-09-28
AU3430700A (en) 2000-10-09
DE60043930D1 (de) 2010-04-15
DE60032120T2 (de) 2007-09-20
AU3813600A (en) 2000-10-09
WO2000056358A2 (en) 2000-09-28
EP1162998B1 (en) 2010-03-03
JP2002539273A (ja) 2002-11-19
NZ513841A (en) 2001-09-28
CZ20013378A3 (cs) 2002-03-13
EP1163000B1 (en) 2008-02-27
JP2011057713A (ja) 2011-03-24
CN1351503A (zh) 2002-05-29
NZ513842A (en) 2004-05-28
BR0009154A (pt) 2001-12-26
ATE387214T1 (de) 2008-03-15
FR10C0008I2 (fr) 2012-10-26
JP2002540074A (ja) 2002-11-26
IL145044A0 (en) 2002-06-30
KR100642044B1 (ko) 2006-11-10
AU3291900A (en) 2000-10-09
BR0009163A (pt) 2001-12-26
NZ513840A (en) 2004-02-27
NO20014323D0 (no) 2001-09-05
SI1162999T1 (sl) 2007-04-30
JP2002540075A (ja) 2002-11-26
EP1776962A1 (en) 2007-04-25
WO2000056360A3 (en) 2001-01-25
US20100119544A1 (en) 2010-05-13
KR20020000785A (ko) 2002-01-05
US20050031646A1 (en) 2005-02-10
BRPI0009163B1 (pt) 2019-04-09
TR200102735T2 (tr) 2002-04-22
BE1025464I2 (OSRAM) 2019-03-06
MY125202A (en) 2006-07-31

Similar Documents

Publication Publication Date Title
BE2018C020I2 (OSRAM)
BE2015C057I2 (OSRAM)
BE2016C007I2 (OSRAM)
BE2015C018I2 (OSRAM)
BE2014C017I2 (OSRAM)
BE2013C051I2 (OSRAM)
BE2013C020I2 (OSRAM)
BE2013C015I2 (OSRAM)
BE2013C001I2 (OSRAM)
BE2012C036I2 (OSRAM)
BE2008C046I2 (OSRAM)
BE1025464I2 (OSRAM)
BE2010C011I2 (OSRAM)
JP2002514480A5 (OSRAM)
BRPI0017527B8 (OSRAM)
BE2008C047I2 (OSRAM)
BE2011C004I2 (OSRAM)
BRPI0001672A2 (OSRAM)
JP2002506962A5 (OSRAM)
BRPI0001542A2 (OSRAM)
BRPI0012675B8 (OSRAM)
BRPI0017522A2 (OSRAM)
BRPI0303609A (OSRAM)
BRMU7902607U2 (OSRAM)
BRPI9917761A2 (OSRAM)